Therapeutics Research Program (TRP)
The evaluation of new drugs and therapeutic agents is a critical aspect of NIAID’s therapeutic research agenda. NIAID-sponsored therapeutics research has already had a dramatic impact on our understanding of the pathogenesis and clinical management of HIV infection over the last decade, and has helped define international guidelines for the treatment of primary HIV infection in adults and children and associated opportunistic infections and prophylactic regimens for these secondary infections, identify biological markers for predicting a drug's effectiveness and disease progression, and set the standard for use of antiretroviral drugs for preventing mother-to-infant transmission.
Within the NIAID, the DAIDS Therapeutics Research Program (TRP), which is divided into four branches: Drug Development and Clinical Sciences Branch, HIV Research Branch, Complications and Co-Infections Research Branch, and the Pediatric Medicine Branch, carries out the following therapeutic research activities:
-
Oversees grants, contracts, and cooperative agreements that support preclinical and clinical therapeutic research, and in particular, the Centers for AIDS Research (CFAR), AIDS Clinical Trials Group (ACTG), International Network for Strategic Initiatives in Global HIV Trials (INSIGHT), and International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT)
-
Develops the scientific agenda for clinical research of therapies to treat HIV and AIDS, related retroviruses, and HIV-related complications and coinfections
-
Promotes research programs to discover novel therapeutic strategies for the treatment of HIV
-
Coordinates research activities in consultation and/or collaboration with other government agencies, international organizations, and other Institutes at the National Institutes of Health.
-
Works with the pharmaceutical industry and the Food and Drug Administration to facilitate the evaluation and approval of new therapeutics
-
Provides scientific guidance to grantees and contractors
For more information on NIAID’s therapeutic research efforts, visit the HIV/AIDS Therapeutics Research Area.
back to top